Carlsmed Sues DeGen Medical Over Eight Spine Surgery Patents
CARL sits 79% above its 52-week low of $8.5.
Summary
Carlsmed filed a patent infringement lawsuit against DeGen Medical in the District of South Carolina, asserting eight patents covering implants, methods, and systems. The company seeks injunctive relief and damages. This is the first legal action of this kind disclosed by Carlsmed and could signal an aggressive defense of its AI-enabled personalized spine surgery IP. The lawsuit follows a favorable CMS reimbursement decision in August and a $250M shelf registration, indicating the company is actively protecting its market position. While the financial impact is uncertain, the case could affect competitive dynamics in the personalized spine surgery space. Watch for DeGen's response and any counterclaims.
At the time of this announcement, CARL was trading at $15.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $415.8M. The 52-week trading range was $8.50 to $17.23. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.